FDA will expedite review of cancer drug Istodax for expanded use

02/28/2011 | Reuters

The FDA granted priority-review status to Celgene's Istodax for use in patients with peripheral T-cell lymphoma who have undergone prior treatment. The agency, which approved the drug for cutaneous T-cell lymphoma, is expected to decide by June 17 on the expanded use.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC